Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 1988Blood

Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does thrombolytic therapy with tissue plasminogen activator or streptokinase induce transient thrombin activity in patients with acute myocardial infarction?

Population

Patients with acute myocardial infarction

Design

Cohort

Follow-up

5 hours

Authors

JOJ OwenAtrium Health Wake Forest BaptistKFKD FriedmanColumbia UniversityBGBA GrossmanColumbia University

Discussion

Loading...

Member takes

Implication

Transient thrombin activity after thrombolysis may raise rethrombosis risk despite heparin; leaves open optimal adjunctive strategies in AMI.

Structured PICO

Does thrombolytic therapy with tissue plasminogen activator or streptokinase induce transient thrombin activity in patients with acute myocardial infarction?

P
Population
Patients with acute myocardial infarction
I
Intervention
Thrombolytic therapy with tissue plasminogen activator or streptokinase, alongside heparin administration
O
Outcome
Plasma level of fibrinopeptide A as a specific index of thrombin activitysurrogate

Thrombolytic therapy with streptokinase or tissue plasminogen activator in acute myocardial infarction induces transient thrombin activity, suggesting a mechanism for potential rethrombosis despite concurrent heparin use.

Cite This Study

Owen et al. (1988) studied this question.

synapsesocial.com/papers/6a7cafd7cc6f1443deba628chttps://doi.org/10.1182/blood.v72.2.616.bloodjournal722616
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity1988 · 232 citations
  2. 2Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.1989 · 116 citations
  3. 3Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.1989 · 105 citations
  4. 4Fibrin Metabolism in Patients with Acute Myocardial Infarction During and After Treatment with Tissue-Type Plasminogen Activator1988 · 10 citations
  5. 5Plasma levels of plasminogen activator inhibitor type 1, beta- thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase1991 · 44 citations